Normal antibody response after COVID-19 during treatment with cladribine

Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies thr...

Descripción completa

Detalles Bibliográficos
Autor principal: Celius, Elisabeth G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832623/
https://www.ncbi.nlm.nih.gov/pubmed/32882501
http://dx.doi.org/10.1016/j.msard.2020.102476
_version_ 1783641877977759744
author Celius, Elisabeth G.
author_facet Celius, Elisabeth G.
author_sort Celius, Elisabeth G.
collection PubMed
description Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies three months later.
format Online
Article
Text
id pubmed-7832623
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-78326232021-01-26 Normal antibody response after COVID-19 during treatment with cladribine Celius, Elisabeth G. Mult Scler Relat Disord Commentary Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies three months later. Elsevier B.V. 2020-11 2020-08-29 /pmc/articles/PMC7832623/ /pubmed/32882501 http://dx.doi.org/10.1016/j.msard.2020.102476 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Commentary
Celius, Elisabeth G.
Normal antibody response after COVID-19 during treatment with cladribine
title Normal antibody response after COVID-19 during treatment with cladribine
title_full Normal antibody response after COVID-19 during treatment with cladribine
title_fullStr Normal antibody response after COVID-19 during treatment with cladribine
title_full_unstemmed Normal antibody response after COVID-19 during treatment with cladribine
title_short Normal antibody response after COVID-19 during treatment with cladribine
title_sort normal antibody response after covid-19 during treatment with cladribine
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832623/
https://www.ncbi.nlm.nih.gov/pubmed/32882501
http://dx.doi.org/10.1016/j.msard.2020.102476
work_keys_str_mv AT celiuselisabethg normalantibodyresponseaftercovid19duringtreatmentwithcladribine

Ejemplares similares